With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the ...

The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.